| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1144: Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) |
|
Medicine details |
|
| Medicine name | spesolimab (Spevigo®) |
| Formulation | Subcutaneous formulation |
| Reference number | 10240 |
| Indication | Treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy |
| Company | Boehringer Ingelheim Limited |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/04/2026 |
| NICE guidance | |